EU and UK merger control in the pharma sector


Competition partner Stephen Smith, of counsel Sean-Paul Brankin and associate Edwin Bond, provide a general overview of the EU and UK merger control regimes. What issues are of particular relevance to the pharmaceutical sector? They cover market definition, price and innovation effects of horizontal mergers, and remedies.

Read the full PDF here.

Topics reviewed include:

  • Particularities of the pharma sector
  • Substantive merger assessment in the pharma sector
  • Jurisdictional aspects of EU merger control: the Article 22 referral mechanism
  • Remedies and appeals
  • Public interest considerations under the UK regime
  • Proposals to amend the UK merger control regime

Reproduced from Practical Law with the permission of the publishers. For further information visit

Stephen Smith


Sean-Paul Brankin


Edwin Bond


Related Articles